Pfizer reaped the rewards of its COVID-19 vaccines and therapeutics in 2022, but there are already signs of falling demand that looks likely to get significantly worse in
Pfizer's decision to raise the price of its COVID-19 vaccine next year has prompted a rebuke from two Democrat senators in the US, who have accused the company of "unseemly profiteering."
A submission to the US Food and Drug Administration (FDA) requesting an Emergency Use Authorization (EUA) of a 10-µg booster dose of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for
Pfizer and BioNTech's COVID-19 vaccine targeting Omicron BA.4 and BA.5 has been recommended for authorisation by the EMA's human medicines committee, shortly after the panel gave its blessi
BioNTech has responded to a patent infringement lawsuit filed by fellow German biotech CureVac over its COVID-19 vaccine, saying it will "vigorously" defend itself.